Blood and plasma products and vaccines maker CSL (CSL) reported its half year numbers today

CommSec

Online Stockbroker

Blood and plasma products and vaccines maker CSL (CSL) reported its half year numbers today. The CSL Group reported a 3.7% rise in sales with total revenue (includes royalties) increasing by 4.8% to US$2.691 billion. The company did take a hit in this result due to the one-off US antitrust class action litigation settlement of US$64 million. CSL will pay a half year dividend of US$0.53. The said it expects FY14 after tax profit growth of around 7% and CSL will continue its current A$950 million share buyback that is now 22% completed. Watch full report here:


CommSec
Online Stockbroker
Online Stockbroker

CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.